Patents by Inventor Sumit Luthra

Sumit Luthra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR STABILIZATION OF LIPID NANOPARTICLE MRNA VACCINES
    Publication number: 20240041785
    Abstract: The present disclosure provides technologies relating to stabilization of lipid nanoparticle mRNA compositions (e.g., vaccines).
    Type: Application
    Filed: November 14, 2021
    Publication date: February 8, 2024
    Inventors: Steffen Panzner, Christian Reinsch, Kaushik Thanki, Sukrut Somani, Serguei A. Tchessalov, Bakul Subodh Bhatnagar, Ramin Darvari, Sumit Luthra
  • LNP COMPOSITIONS COMPRISING RNA AND METHODS FOR PREPARING, STORING AND USING THE SAME
    Publication number: 20230414747
    Abstract: The present disclosure relates generally to the field of lipid nanoparticle (LNP) compositions comprising RNA, methods for preparing and storing such compositions, and the use of such compositions in therapy.
    Type: Application
    Filed: November 15, 2021
    Publication date: December 28, 2023
    Inventors: Steffen Panzner, Ugur Sahin, Jorrit-Jan Krijger, Kaushik Thanki, Bakul Subodh Bhatnagar, Ramin Darvari, Sumit Luthra, Serguei A. Tchessalov
  • ENHANCED FORMULATION STABILIZATION AND IMPROVED LYOPHILIZATION PROCESSES
    Publication number: 20230414516
    Abstract: This invention relates to enhanced stabilization and improved lyophilization methods of pharmaceutical substances.
    Type: Application
    Filed: November 15, 2021
    Publication date: December 28, 2023
    Inventors: Bakul Subodh Bhatnagar, Ramin Darvari, Sumit Luthra, Serguei A. Tchessalov, Steffen Panzner, Christian Reinsch, Kaushik Thanki, Sukrut Somani
  • Formulations of a PI3K/mTOR-inhibitor for intravenous administration
    Patent number: 10660959
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: May 26, 2020
    Assignee: Pfizer Inc.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION
    Publication number: 20190105390
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Application
    Filed: November 13, 2018
    Publication date: April 11, 2019
    Applicant: PFIZER INC.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • Formulations of a PI3K/mTor-inhibitor for intravenous administration
    Patent number: 10172942
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: January 8, 2019
    Assignee: Pfizer Inc.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra
  • FORMULATIONS OF A PI3K/MTOR-INHIBITOR FOR INTRAVENOUS ADMINISTRATION
    Publication number: 20170360935
    Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising -(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable salt thereof, that is a clear solution. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.
    Type: Application
    Filed: December 10, 2015
    Publication date: December 21, 2017
    Applicant: PFIZER INC.
    Inventors: Kevin Richard Back, Michael Cram, Aidan James Harper, W. James Huang, Jonathan Richard Lillis, Timothy Michael Lukas, Sumit Luthra